This study suggests that treatment with an HDAC inhibitor enhances the cytotoxicity of cisplatin therapy in ovarian and breast cancer cells and that this increased sensitivity may be mediated by a BRCA1 mechanism. This evidence concerns the gene BRCA1 and breast cancer.